论文部分内容阅读
为了解2型糖尿病及其血管并发症患者血清ACE(SACE)活性的变化， 采用比色法对1 27例2型糖尿病患者和90例正常人进行SACE活性的检测。结果显示：糖尿病患者SACE活性(45 9. 51±175.85U)明显高于正常人(321.14±121.27U)；糖尿病肾病组SACE活性(548.27±166.60 U)明显高于非肾病组(383.20±139-00U)，但微量蛋白尿组(528.10±190.70U)与大量蛋白 尿 组(545.83±138.60U)SACE活性比较无统计学意义(P＞005)；糖尿病视网膜病变 组SACE活性(465.64±178.93 U)与无视网膜病变组(449.07±170.04U)比较也无统计学意义；糖尿病患者SACE活性与病程 、 血压、血脂和血糖无关。提示ACE可能仅参与了糖尿病和糖尿病肾病的发病，而与糖尿病肾 病进行性发展、糖尿病视网膜病变和高血压发病无关。
To understand the changes of serum ACE (SACE) activity in patients with type 2 diabetes mellitus and its vascular complications, colorimetry was used to detect SACE activity in 272 type 2 diabetic patients and 90 normal subjects. The results showed that SACE activity in diabetic patients was significantly higher than that in healthy controls (45 9. 51 ± 175.85U vs 321.14 ± 121.27U vs 548.27 ± 166.60 U vs 383.20 ± 139- (P <0.05). However, the SACE activity in microalbuminuria group (528.10 ± 190.70U) and macroalbuminuria group (545.83 ± 138.60U) was not statistically significant (P> 0.05). SACE activity in diabetic retinopathy group (465.64 ± 178.93 U) had no statistical significance compared with those without retinopathy (449.07 ± 170.04U). The activity of SACE in diabetic patients was not related to the course of disease, blood pressure, blood lipids and blood glucose. Suggesting that ACE may only participate in the pathogenesis of diabetes and diabetic nephropathy, but with the progressive development of diabetic nephropathy, diabetic retinopathy and hypertension incidence.